DR NOELLE SUNSTROM
Chief Executive Officer
Dr Sunstrom has been the CEO of NeuClone since it was established in 2007. Dr Sunstrom has over 20 years experience in the biopharmaceutical industry including more than 10 years of executive experience in biopharmaceutical companies. Dr Sunstrom has led teams in product development from bench to the market and founded and led two biotechnology companies based on CHO cell line development. Dr Sunstrom has held previous positions as CSO and Co-Founder of Acyte Biotech Pty Ltd as well as Deputy Director of both the CRC for Biopharmaceutical Research and the Bioengineering Centre at the University of New South Wales.
DR ANGELO PERANI
Chief Scientific Officer
Dr Angelo Perani has over 15 years experience in Mammalian Cell Culture working for the Ludwig Institute for Cancer Research and Lonza Biologics. He holds a European PhD from the INPL-France on Apoptosis in Mammalian Cell Culture and its applications to the production of monoclonal antibodies from a joint project between the INSERM U284 in France, the European Cell Bank (ECACC) in the UK and the University of Barcelona in Spain. This was followed by a post-doc fellowship at the Animal Cell Technology Group (University of Birmingham UK) investigating the impact of over-expressing bcl-2 in industrial cell lines. He was also responsible of an EU-funded project “Suppression of Apoptosis in Large Scale Biological Production Systems” in collaboration with Hamburg-Harburg University in Germany.
Global Head of Business Development and Alliances
John Oksinski is a former executive of Merck & Co., Inc., serving in various roles until 2009 including Executive Director, Business Development, Asia Pacific, and in a separate assignment, Executive Director, Business Development, Japan. From 2009-2012, he was Head of Asia Pacific/Japan, Corporate Development at GlaxoSmithKline. More recently, John worked with The George Institute for Global Health, leading an entrepreneurial ‘for-profit’ venture focused on developing low-cost, highly effective drug treatments for the world’s emerging markets. John holds a Master of Commerce Degree (UNSW), is a Fellow of the Institute of Public Accountants, and is a Graduate of the Australian Institute of Company Directors.
GLENN R PILKINGTON
Director of Clinical Development
Glenn has 20 years of biotech industry experience, with approximately 15 years at management level. His first 11 years were spent in the USA biotech industry, at Intracel Corporation and GlaxoSmithKline spinout, diaDexus LLC. During this time he collaborated successfully with scientists at Thomas Jefferson University, NIH, CDC, California Department of Health and Baylor College of Medicine. Since that time he has worked in management roles at Apollo Life Sciences and Biosceptre International, in the Sydney area, developing therapeutic protein based products, to Phase I and II stage. At Intracel Glenn established a laboratory for discovery of fully human monoclonal antibody products against infectious diseases (RSV, HIV, CMV, hepatitis A, B & C), inflammatory diseases (anti-huCD4) and human tumor associated antigens (huCD20 & colon cancer).